AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock Information for AN2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AN2 Therapeutics Inc.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.